NCT00645892View on ClinicalTrials.gov

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

September 30, 2004

Conditions

Psoriasis

Interventions

DRUG

adalimumab

OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24

DRUG

placebo for adalimumab

OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Abbott

INDUSTRY